Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
NCT ID: NCT00425256
Last Updated: 2011-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2006-02-28
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sexual Function Trial of Overactive Bladder: Medication Versus PTNS
NCT03500146
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
NCT00911937
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
NCT04023253
Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients
NCT00713921
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
NCT00857896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bremelanotide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In a stable relationship with a male partner for at least 6 months
* Willing to attempt sexual activity once a week with your partner
21 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
INDUSTRY
Palatin Technologies, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Palatin Technologies, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Affiliated Research Center
Huntsville, Alabama, United States
Quality of Life Medical & Research Center, LLC
Tucson, Arizona, United States
University of California, Department of Family and Preventative Medicine
La Jolla, California, United States
Downtown Women's Health Care
Denver, Colorado, United States
Coastal Connecticut Research
New London, Connecticut, United States
South Florida Medical Research
Aventura, Florida, United States
Clinical Study Center
Fort Myers, Florida, United States
Center For Marital and Sexual Health of South Florida
West Palm Beach, Florida, United States
Northeast Indiana Research
Fort Wayne, Indiana, United States
Center for Sexual Medicine at Sheppard Pratt
Baltimore, Maryland, United States
Advanced Biomedical Research, Inc
Hackensack, New Jersey, United States
The Center for Female Sexuality
Purchase, New York, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
Lyndhurst Gynecologic Associates
Winston-Salem, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Medford Women's Clinic, LLP
Medford, Oregon, United States
Clinical Trials Research Services, LLC
Pittsburgh, Pennsylvania, United States
Advanced Clinical Therapies, Inc.
West Reading, Pennsylvania, United States
Accelovance
Houston, Texas, United States
Women's Clinical Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PT-141-2005-53
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.